U.S. Entertainment Stock News

In February 2026, SEALSQ and Lattice Semiconductor announced a collaboration to embed TPM-based post-quantum cryptography into select Lattice FPGAs, alongside Lattice’s separate launch of a Cyber Resilience Reference Kit with EXOR International and TrustiPhi to support secure industrial and edge device design. Together, these security-focused partnerships underscore how Lattice is tying its low-power FPGA portfolio more tightly to emerging quantum-safe and cyber resilience requirements in...

In the days leading up to its 24 February 2026 earnings release, Apellis Pharmaceuticals faced expectations of a year-over-year decline in quarterly earnings and revenue, alongside a negative Earnings ESP of 3.07% and increasingly cautious analyst projections. This shift in sentiment, driven by concerns over weaker near-term performance, highlights how quickly earnings expectations can reshape perceptions of Apellis’ long-term prospects. Now, we’ll explore how this weaker earnings outlook...

Celcuity Inc. recently appointed Charles (Chip) R. Romp, a veteran oncology-focused pharmaceutical executive and current CEO of Secura Bio, to its Board of Directors, adding more than 25 years of commercial and sales leadership experience to the company. Romp’s track record helping build commercial franchises for oncology drugs at Seagen and Genentech adds board-level insight that aligns directly with Celcuity’s focus on bringing targeted cancer therapies to market. We’ll now look at how...

Costco Wholesale (NasdaqGS:COST) recently won a legal case tied to U.S. tariffs, clarifying its eligibility for tariff refunds. The Supreme Court ruled that certain Trump-era tariffs were unconstitutional, opening the door for companies like Costco to seek refunds. Costco previously filed suit to preserve its rights to future tariff refunds, which could affect its cost structure and pricing. The company is also moving ahead with international expansion, targeting 28 new warehouses this...

Equinix (NasdaqGS:EQIX) has announced that Chief Sales Officer Mike Campbell will retire and move into a Special Advisor role. The transition marks a change in the company’s executive leadership structure focused on sales and customer engagement. For investors watching Equinix at a share price of $928.11, this leadership change comes after a period of solid share price moves, with the stock up 17.3% over the past 30 days and 21.5% year to date. Over longer horizons, Equinix has delivered...

Waters (WAT) is in focus after closing a transaction that reorganizes the company into four divisions, alongside fresh 2026 guidance, detailed 2025 results, and a new genome scientist joining its board. See our latest analysis for Waters. The reorganization, fresh 2026 guidance and board refresh come after a mixed stretch for the stock, with a 1-day share price return of 1.42% and 7-day gain of 3.08% alongside a 30-day share price decline of 15.03%. The 5-year total shareholder return of...

In February 2026, Vonage announced a collaboration with C3.ai to launch C3 AI Field Services, an AI-first mobile module that embeds Vonage’s voice, video, and network APIs into C3.ai’s Asset Performance Suite to support complex, real-time field operations. The launch highlights how C3.ai is positioning its enterprise AI platform at the intersection of connectivity and on-the-ground industrial workflows, aiming to make AI agents directly usable by technicians rather than just data...

If you are wondering whether Realty Income is fairly priced or offering value right now, this article will walk through what the current numbers are saying about the stock. With the share price at about US$66.14 and total returns of 0.7% over 7 days, 8.9% over 30 days, 15.4% year to date and 22.5% over 1 year, recent moves may have shifted how investors think about both upside and risk. Recent news coverage around Realty Income has largely focused on its role as a large net lease real estate...

Why the new class action matters for uniQure investors Kessler Topaz Meltzer & Check has filed a securities fraud class action against uniQure (NasdaqGS:QURE), alleging misleading statements about FDA alignment and timelines for AMT-130, its Huntington’s disease gene therapy program. See our latest analysis for uniQure. uniQure’s latest share price of US$23.43 comes after a 7 day share price return of 14.29%. However, the 90 day share price return of a 15.66% decline and 5 year total...

Ramaco Resources (METC) has been drawing attention after a sharp decline in its share price over the past month, even as its past 3 months return, one year total return, and longer term performance figures remain positive. See our latest analysis for Ramaco Resources. The recent 40.26% 1 month share price decline to US$16.56 sits against a much stronger backdrop, with a 1 year total shareholder return of 73.74% and multi year total shareholder returns still firmly positive. This suggests...

Orrum Clinical Analytics recently announced a partnership with LivaNova USA Inc. to link LivaNova’s Essenz Perfusion System with Orrum’s CORE Insights platform, enabling automatic transfer of perfusion case data for post-operative analysis and peer benchmarking. By extending Essenz data into a secure analytics environment that supports evidence-based performance improvement, the collaboration could strengthen LivaNova’s positioning in data-driven cardiopulmonary care and potentially appeal...

Earlier this month, International Seaways commented that tightening energy supplies due to sanctions and rising oil demand are reshaping global crude and product shipping patterns, directly affecting its tanker operations. The company highlighted that more complex, longer trade routes could meaningfully influence its operational outlook, potentially altering how it deploys its fleet and prioritizes future opportunities. We'll now examine how management’s views on tightening sanctioned supply...

In February 2026, OPENLANE, Inc. reported full-year 2025 results showing revenue of US$1.93 billion and net income of US$177.7 million, while also recording a basic and diluted loss per share of US$0.96 from continuing operations. The company also issued 2026 guidance calling for income of US$130 million to US$147 million and diluted net income per share of US$0.95 to US$1.09, sharpening investor focus on how its mix of continuing and discontinued operations affects reported...

In February 2026, Housecall Pro announced a new native integration with Yelp, allowing Yelp’s high-intent Request a Quote leads to flow directly into Housecall Pro’s Job Inbox for home service professionals across the U.S. and Canada. A day earlier, Yelp reported fourth-quarter 2025 results showing roughly flat quarterly revenue year over year, alongside full-year revenue growth and new 2026 net revenue guidance of US$1.46–US$1.48 billion as it continues investing in AI-powered...

Consumer Watchdog recently criticized the California Energy Commission for not using its legislative powers to prevent gasoline price spikes after Valero had informed it a year in advance about planned unit shutdowns at the Benicia refinery, which was originally expected to keep operating through April under an agreement. The advocacy group is now urging legislative oversight hearings and new rules on refinery inventories and resupply, putting fresh regulatory attention on Valero’s role in...

Event context and recent performance Hartford Insurance Group (HIG) has drawn fresh investor attention after a recent price move, with the stock closing at $142.19. That sits alongside a 10.6% return over the past month and 4.1% over the past 3 months. See our latest analysis for Hartford Insurance Group. Zooming out, Hartford Insurance Group’s recent 1 day and 1 month share price gains sit against a year to date share price return of 3.7%, while its 1 year total shareholder return is 29.8%...

PharmaPack launch puts Harrow stock in focus Harrow (HROW) has drawn fresh attention after launching PharmaPack, a direct-to-prescriber cash-pay program offering FDA-approved ophthalmic kits intended to replace off-label compounded products used around cataract surgery. See our latest analysis for Harrow. The PharmaPack announcement comes as Harrow’s short term share price momentum is strong, with a 1 month share price return of 16.93% and a 90 day share price return of 26.77%, set against a...

Why Campbell's Stock Is Back in Focus Campbell's (CPB) has drawn fresh attention after its recent name change from Campbell Soup Company to The Campbell's Company, shifting the spotlight to how its current valuation lines up with fundamentals. See our latest analysis for Campbell's. The recent name change comes against a weaker share price backdrop, with a 7 day share price return showing a 9.02% decline and a 1 year total shareholder return showing a 31.79% decline, suggesting sentiment has...

If you are wondering whether New York Times shares still offer value after a strong run, you will want to look closely at what different valuation methods are saying about the current price. The stock last closed at US$77.99, with returns of 6.9% over 7 days, 7.9% over 30 days, 11.7% year to date, 64.4% over 1 year and 106.5% over 3 years. This naturally raises questions about how much of the story is already reflected in the share price. Recent attention around New York Times has focused on...

Helmerich & Payne’s joint venture Turan Drilling and Engineering recently secured a long-term offshore operations and maintenance contract renewal from BP in the Caspian Sea, covering eight platforms over a firm five-year term with three optional one-year extensions and a potential value above US$1.00 billion. This renewal highlights the company’s growing international service footprint and reinforces the importance of offshore partnerships in complementing its largely onshore-focused...

If you are wondering whether Ovintiv's share price still offers value at current levels, it helps to step back and look at what the market might be pricing in. The stock closed at US$50.58, with returns of 7.8% over the last 7 days, 23.3% over the last 30 days, 24.9% year to date, 20.3% over 1 year, 20.9% over 3 years, and 147.0% over 5 years. Recent news around Ovintiv has largely focused on its position in the US energy sector and how investors are weighing commodity price moves against...

If you are wondering whether Procter & Gamble at around US$160.78 is giving you fair value for a long term consumer staples holding, this article is designed to walk you through that question clearly. The share price return data is mixed, with the stock showing 0.4% over the last week, 7.1% over the last month, 13.4% year to date, 24.6% over 3 years and 47.7% over 5 years, while the 1 year figure stands at a 3.0% decline. Recent commentary around Procter & Gamble has focused on how a large,...

Halozyme Therapeutics (NasdaqGS:HALO) reported a quarterly net loss after recording a major impairment charge. The company outlined plans to actively pursue acquisitions to expand its drug delivery portfolio. These developments come alongside strong revenue growth in the latest quarter. Halozyme Therapeutics, trading at $70.98, is coming off a mixed stretch, with the share price down 10.6% over the past week but up 22.9% over the past year and 56.9% over five years. For investors, the...

Fidelity National Information Services (FIS) is back in focus ahead of its upcoming earnings report, with expectations for year-over-year growth in earnings and revenue, plus fresh hedge fund interest in the oversold stock. See our latest analysis for Fidelity National Information Services. At a share price of $49.13, Fidelity National Information Services has seen a 4.98% 7 day share price return, but a 25.13% decline year to date and a 60.22% drop in 5 year total shareholder return, which...